Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
PHASE1CompletedINTERVENTIONAL
Enrollment
15
Participants
Timeline
Start Date
May 12, 2016
Primary Completion Date
June 7, 2021
Study Completion Date
June 7, 2021
Conditions
Hodgkin's LymphomaLymphoma, Non-Hodgkin
Interventions
DRUG
Bortezomib
DRUG
Ruxolitinib
Trial Locations (1)
48187
University of Michgan Comprehensive Cancer Center, Ann Arbor
All Listed Sponsors
lead
University of Michigan Rogel Cancer Center
OTHER
NCT02613598 - Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | Biotech Hunter | Biotech Hunter